Introduction
Sipoglitazar, 3-[3-ethoxy-1-[[4-[(2-phenyl-1,3-thiazol-4-yl) Among the metabolites, M-I and sipoglitazar-G were shown to be the key metabolites in the elimination process, because sipoglitazar was mainly excreted into the feces via biliary excretion as sipoglitazar-G in rats and M-I was detected as the main metabolite in the monkey plasma. Furthermore, metabolite M-I was also measured as the main metabolite in plasma of humans orally administered sipoglitazar.
In the present paper, to clarify the metabolic pathways from sipoglitazar to M-I in humans, in vitro metabolic studies using human hepatocytes and hepatic microsomes, identification of metabolites by LC-MS/MS and NMR and a stability study of the metabolites were carried out.
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Other Materials
Cryopreserved primary human hepatocytes (Lot No. 69 , from a 63-year-old female, Caucasian) were obtained from Celsis In Vitro Technologies (Baltimore, MD In the course of this study, the glucuronide of sipoglitazar, sipoglitazar-G was revealed to be composed of two glucuronides, which were defined as sipoglitazar-G1 and sipoglitazar-G2. The column temperature was set at 40°C for the structural analysis.
Incubation of [

C]sipoglitazar with Human Hepatocytes
Cryopreserved hepatocytes were suspended using published procedures with minor modifications (Loretz et al., 1989; Li et al., 1999) . Hepatocytes, suspended in 0. 
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-10 -voltage; 3.0 V. The collisionally induced dissociation (CID) fragment ions were generated using helium as a target gas, and the CID energy was 40%. For TSQ-7000 (target analytes:
sipoglitazar-G1 and -G2), heated capillary temperature; 230°C, spray voltage; 4.5 kV, and sheath gas pressure; 483 kPa. The CID fragment ions were generated within quadrupole 2, using argon as a target gas, and the CID energy (quadrupole 2 offset voltage) and the target gas pressure were -25 eV and 0. 
Analytical Procedures for [ 14 C]sipoglitazar and its Metabolites
The incubation procedures described above were terminated by the addition of acetonitrile at a volume equivalent to the volume of the reaction mixture and centrifuging at approximately 1500xg for 10 minutes. The supernatant was analyzed by an HPLC (LC-10 gradient system; Shimadzu Corp., Kyoto, Japan) with an on-line RI detector (D505TR Flow Scintillation Analyzer, Packard Instrument Company, Meriden, CT). The typical HPLC analytical method was as follows: separation of the metabolites was carried out on an Inertsil ODS-3 (5-µm particle size, 150 or 250 x 4.6 mm I.D.; GL Sciences, Tokyo, Japan) at 40°C or 4°C, following gradient elution using acetonitrile, H 2 O and trifluoroacetic acid (TFA). The acetonitrile concentration was increased from 34% to 66% over a period of 40 minutes and held at 86% for 10 minutes. Throughout the elution, the flow of 0.1% of TFA was continued and the flow rate was 0.5 or 1 mL/minutes. On-line RI detection was carried out using Ultima-Flo as the flow scintillation cocktail.
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Results
Metabolic Profiles of [ 14 C]sipoglitazar with Hepatocytes and Hepatic Microsomes from Humans
The metabolic profile of [ 14 C]sipoglitazar was examined using hepatocytes and hepatic microsomes from humans ( Figure 1 ). In the reactions with hepatocytes, the deethylated metabolite (M-I) and the glucuronide conjugate of sipoglitazar (sipoglitazar-G) were the main metabolites and the hydrolyzed metabolite (M-II) was also detected as a minor metabolite.
To separate the reactions of oxidation and glucuronidation, metabolic studies using hepatic microsomes with/without their cofactors, NADPH-generating system and UDPGA were conducted. When both an NADPH-generating system and UDPGA were added, the metabolites were detected with similar profiles in the reactions with hepatocytes. Addition of only an NADPH-generating system to the reaction mixture resulted in the formation of M-II, and a limited amount of M-I. When only UDPGA was added to the microsomal reaction mixture, sipoglitazar-G was formed extensively.
Preparation of Sipoglitazar-G1 and Sipoglitazar-G2
In the course of metabolic analysis of sipoglitazar-G formed by hepatic microsomes, sipoglitazar-G in the reaction mixture was revealed to consist of two isomers. In the HPLC analysis with the column set at 40°C, sipoglitazar-G was detected as one peak (Figure 2A ), This article has not been copyedited and formatted. The final version may differ from this version. -15 -but two separate peaks originating from sipoglitazar-G were detected, when the temperature of the column for HPLC analysis was changed to 4°C and these were named sipoglitazar-G1
and sipoglitazar-G2 according to the elution order ( Figure 2B ).
LC-MS/MS Analysis of Sipoglitazar-G1 and Sipoglitazar-G2
To elucidate the properties of the two types of sipoglitazar glucuronides, 
NMR Analysis of Sipoglitazar-G1 and Sipoglitazar-G2
To determine the site of glucuronidation of sipoglitazar-G1 and sipoglitazar-G2, an 1 H-NMR spectrum analysis was performed (Table 1 
Stability and Interconversion of Sipoglitazar-G1 and Sipoglitazar-G2
To investigate the stability and interconversion between [ 14 C]sipoglitazar-G1 and sipoglitazar-G2 were stable and neither degradation nor interconversion was observed. In both KPB (pH 7.4) and rat bile, similar composition change was shown and sipoglitazar-G1
was gradually eliminated to form sipoglitazar-G2 and sipoglitazar. Sipoglitazar-G2 was slightly eliminated to form sipoglitazar, but conversion from sipoglitazar-G2 to -G1 was not observed. More significant deglucuronidation and sipoglitazar-G1-to-G2 conversion were also observed in rat bile.
In human plasma, sipoglitazar-G1 was converted to sipoglitazar-G2 immediately after the mixing with human plasma and thereafter both sipoglitazar-G1 and sipoglitazar-G2 were gradually eliminated to form sipoglitazar.
Sipoglitazar-G2 was gradually eliminated to form sipoglitazar, but conversion from sipoglitazar-G2 to -G1 was not observed. These results indicate that sipoglitazar-G1 could be converted to sipoglitazar-G2 and then to sipoglitazar from both sipoglitazar-G1 and -G2.
Oxidative Metabolisms of Sipoglitazar-G1 and Sipoglitazar-G2 
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-18 -sipoglitazar-G2 could not detected separately, therefore the interconversion between sipoglitazar-G1 and sipoglitazar-G2 could not be evaluated.
Identification of the CYP Isoform Involved in the Metabolism of [ 14 C]sipoglitazar-G1
The CYP isoform involved in the formation of M-I from sipoglitazar-G1 was identified by a metabolic study using microsomes expressing human CYP isoforms and a correlation study using hepatic microsomes from 16 individual humans ( Figure 7 and Table 2 ).
CYP2C8-expressing microsomes showed extensive activity to form M-I (Figure 7 ). In the correlation study, the elimination rate of [ 14 C]sipoglitazar-G1 and the formation rate of M-I correlated most strongly with paclitaxel 6α-hydroxylase activity (CYP2C8) ( Table 2) .
Sipoglitazar-G1 elimination and M-I formation were also correlated with the S-mephenytoin N-demethylation activity (CYP2B6) and chlorzoxazone 6-hydroxylation activity (CYP2E1).
However, sipoglitazar-G1 was hardly metabolized by CYP2B6 and CYP2E1 enzymes ( Figure   7 ). From these results, CYP2C8 is considered to be the main CYP isoform involved in the formation of M-I from sipoglitazar-G1.
The Effect of Gemfibrozil on the in vitro Oxidative Metabolism and/or Glucuronidation of [ 14 C]sipoglitazar
In the presence of both an NADPH generating system and UDPGA, sipoglitazar was metabolized to M-I, M-II, sipoglitazar-G1, sipoglitazar-G2, and unidentified metabolites.
This article has not been copyedited and formatted. The final version may differ from this version. Elimination of sipoglitazar and formation of M-I, and M-II were inhibited by gemfibrozil, and the relative activities at 300 μ mol/L of gemfibrozil were 58.7%, 9.1%, and 13.4%, respectively (Figure 8 ). However, sipoglitazar-G1 formation was increased rather than inhibited and the relative activities at 10, 30, 100, and 300 μ mol/L of gemfibrozil were 103.5%, 110.3%, 130.3%, and 125.9%, respectively.
In the presence of UDPGA without an NADPH generating system, sipoglitazar was mainly metabolized to sipoglitazar-G1. Elimination of sipoglitazar and formation of sipoglitazar-G1 were inhibited by gemfibrozil and the relative activities at 300 μ mol/L of gemfibrozil were 66.8% and 65.7%, respectively (Figure 8 ).
This article has not been copyedited and formatted. The final version may differ from this version. (Table 1 , Figures 3 and 4) . These results showed that the sipoglitazar-G1 has been detected only in in vitro studies, while the sipoglitazar-G detected in the in vivo studies was sipoglitazar-G2.
To clarify the reason why only sipoglitazar-G2 was detected in in vivo studies, the stability and interconversion of the sipoglitazar glucuronides were examined. The different properties of these isomers between sipoglitazar-G1 and sipoglitazar-G2 were caused by irreversible internal migration of the glucuronides ( Figure 5 ). In the neutral condition, sipoglitazar-G1 was converted to sipoglitazar-G2, while sipoglitazar-G1 was not formed from sipoglitazar-G2. Moreover, sipoglitazar was formed by deconjugation from both sipoglitazar-G1 and sipoglitazar-G2. These conversions were significantly observed in rat bile and human plasma. From these results, it is believed that sipoglitazar-G1 is rapidly converted to sipoglitazar-G2 and sipoglitazar and is biotransformed to M-I simultaneously in This article has not been copyedited and formatted. The final version may differ from this version. in vivo conditions. Therefore, it is considered that of the two isomers, only sipoglitazar-G2 was detected in vivo. Such conversion is generally known with acyl glucuronides where β -1-O-acyl glucuronide is irreversibly converted to 2-O-isomer (Skordi et al., 2005) . The rates of acyl migration depend on the temperature and pH, with such compounds being more stable in cold acidic conditions (Dickinson et al., 1984; Smith et al., 1985; Hyneck et al., 1988) , and also depending on the solvent (Smith et al., 1985; Mortensen et al., 2002) and the nature of the aglycon (Nicholls et al., 1996; Vanderhoeven et al., 2004) . These properties of the acylglucuronides would support the clarification of the metabolic pathway of sipoglitazar.
To elucidate the metabolic pathways of sipoglitazar, [ 14 C]sipoglitazar-G1 and [ 14 C]sipoglitazar-G2 were metabolized by human hepatic microsomes with and without an NADPH-generating system ( Figure 6 ). In either condition, deglucuronidation of both sipoglitazar-G1 and sipoglitazar-G2 were observed. In contrast, formation of M-I was observed only from sipoglitazar-G1 and the reaction was dependent on the presence of NADPH, while M-I was not formed from sipoglitazar-G2. These results indicate that CYP may be involved in the formation of M-I from sipoglitazar-G1. Further investigations to identify the CYP isoform revealed that CYP2C8 was involved in the oxidation of sipoglitazar-G1 (Table 2 and Figure 7 ). In total, it is considered that M-I formation is via the oxidation of sipoglitazar-G1 by CYP2C8 and it was clarified that the glucuronide is a substrate for oxidative metabolism by CYP.
This unusual metabolic pathway has been already reported that glucuronides of diclofenac, This article has not been copyedited and formatted. The final version may differ from this version. 
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-23 -β -estradiol and MRL-C could be a substrate for oxidative metabolism by CYP (Kumar et al., 2002; Delaforge et al., 2005; Kochansky et al., 2005) . CYP2C8 is also involved in the oxidation of these compounds. These compounds are supposed to have easier access to the active site of CYP2C8 by the polarization of the compound by glucuronidation. This finding is a common feature with CYP2C8 substrates, revealed from the pharmacophore analysis of CYP2C8; CYP2C8 substrates have a long hydrophobic chain with an acidic or polar group and a hydrophobic or aromatic moiety and another structural feature of CYP2C8 likely causing this is an active site, Arg Melet et al., 2004; Johnson et al., 2005) . Although sipoglitazar also has a similar structural property, there was a big difference between sipoglitazar and these compounds. Interestingly, M-I was formed only when sipoglitazar was metabolized via glucuronidation, while the position subject to oxidation in the glucuronides of diclofenac and MRL-C could be also oxidized by other CYPs and their glucuronidation was not always essential to form their oxidative metabolites.
This difference suggests that the metabolism of sipoglitazar-G1 is more CYP2C8-selective than that of the other compounds, and makes the metabolic pathway of sipoglitazar very unique. Furthermore, gemfibrozil-1-O-β-glucuronide is well known as CYP2C8 inhibitor and could cause drug-drug interactions at the level of transporters (Ogilvie et al., 2006; Baer et al., 2009; Shitara et al., 2004) . Sipoglitazar also has a similar property with gemfibrozil in terms of the structure and the involvement of CYP2C8 in its metabolic pathway. The Each ratio of radioactivity of sipoglitazar (•), sipoglitazar-G1 (□) and sipoglitazar-G2 (▲) was expressed, while the total radioactivity in the incubation mixture is regarded as 100%. 
